摩尔线程：目前新产品和新架构均处于在研阶段 量产及产生收入仍需一定时间 信立泰：筹划发行H股并在香港联交所上市 专题：交易提示 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【热点】 新宙邦：拟发行H股股票并在香港联交所上市 【并购重组】 新兴铸管：子公司拟12.44亿元收购华润制钢100%股权 兆新股份：拟收购新能源运维企业优得新能源70%股权 威高骨科：拟通过收购及增资方式取得杰思拜尔55%股权 易成新能：拟1000万元收购开封时代7.69%股权 蓝盾光电：终止购买星思半导体部分股权 【股权变动】 胜通能源：控股股东将变更为七腾机器人 股票复牌 南都电源：控股股东筹划控制权变更事项 股票停牌 维宏股份：控股股东拟减持不超过1.15%公司股份 美凯龙：淘宝控股及新零售基金减持3061.6万股公司H股 【中标合同】 宇晶股份：签署2859.68万美元销售合同 中威电子：公司实控人将变更为付英波 股票复牌 【增减持、回购】 真兰仪表：董事长之一致行动人拟增持公司股份 阳光乳业：控股股东的一致行动人拟减持不超3%公司股份 洛凯股份：股东拟合计减持公司不超3%股份 吉峰科技：拟与东台联飞 ...

【头条要闻】 5个必须、8项任务，中央重要会议细化明年经济工作！最新看点来了 12月11日召开的中央经济工作会议总结2025年经济工作，分析当前经济形势，部署2026年经济工作。继 12月8日中央政治局会议分析研究2026年经济工作，提出明年八大重点任务后，中央经济工作会议在此 基础上进一步细化重点任务的政策安排和目标，并在财政货币政策、政策关键着力点等方面提出具体部 署。 值得注意的是，会议认为，通过实践，我们对做好新形势下经济工作又有了新的认识和体会：必须充分 挖掘经济潜能，必须坚持政策支持和改革创新并举，必须做到既"放得活"又"管得好"，必须坚持投资于 物和投资于人紧密结合，必须以苦练内功来应对外部挑战。[最新定调2026年房地产政策]["八个坚持"释 放哪些信号？] [要点极简版][相关专题] 多家国际机构上调中国经济增速预期 近日多家国际机构密集上调2025年中国经济增速预期。其中，世界银行、国际货币基金组织、亚洲开发 银行分别上调0.4、0.2、0.1个百分点。 多家机构表示，尽管面临冲击，中国经济展现了显著韧性。世行12月11日发布最新一期中国经济简报， 相较上期简报，对2025年中国经济增速预 ...

阳光诺和：拟2000万元投资弼领生物 【热点】 摩尔线程：目前新产品和新架构均处于在研阶段 量产及产生收入仍需一定时间 信立泰：筹划发行H股并在香港联交所上市 新宙邦：拟发行H股股票并在香港联交所上市 【并购重组】 新兴铸管：子公司拟12.44亿元收购华润制钢100%股权 兆新股份：拟收购新能源运维企业优得新能源70%股权 威高骨科：拟通过收购及增资方式取得杰思拜尔55%股权 易成新能：拟1000万元收购开封时代7.69%股权 蓝盾光电：终止购买星思半导体部分股权 【股权变动】 胜通能源：控股股东将变更为七腾机器人 股票复牌 南都电源：控股股东筹划控制权变更事项 股票停牌 中威电子：公司实控人将变更为付英波 股票复牌 【增减持、回购】 真兰仪表：董事长之一致行动人拟增持公司股份 阳光乳业：控股股东的一致行动人拟减持不超3%公司股份 洛凯股份：股东拟合计减持公司不超3%股份 维宏股份：控股股东拟减持不超过1.15%公司股份 美凯龙：淘宝控股及新零售基金减持3061.6万股公司H股 【中标合同】 宇晶股份：签署2859.68万美元销售合同 吉峰科技：拟与东台联飞签订合作框架协议 金智科技：公司及子公司合计中标76 ...

Core Viewpoint - The approval of the "Coronary Scoring Balloon Dilatation Catheter" by the National Medical Products Administration (NMPA) represents a significant advancement for the company in providing effective solutions for complex coronary artery diseases [1][2]. Product Information - The product, named "Star Scar," features a unique spiral triangular scoring wire that allows for 360° efficient pressure-focused dilation [1]. - It is the only coronary scoring balloon with up to four scoring wires, providing a larger scoring area and a rated burst pressure (RBP) of up to 20 atm, enhancing safety during expansion [1]. - The device is particularly advantageous for treating calcified and high-resistance complex lesions, offering a safer and more ideal choice for coronary intervention [1]. Impact on the Company - The successful approval of the Star Scar catheter not only provides a precise and efficient pre-dilation option for complex coronary artery lesions but also completes the strategic puzzle for the company's cardiovascular division in constructing a "PCI optimization full-link solution" [2]. - This development is expected to positively influence the company's operational growth by enabling a comprehensive solution for both simple and complex lesions in PCI treatments [2].

Core Viewpoint - Blue Sail Medical (002382.SZ) has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its self-developed and produced Class III medical device, the "Coronary Scoring Balloon Dilatation Catheter" (branded as "Star Scar™") [1] Group 1: Product Features - The Star Scar™ catheter features a unique spiral-wound triangular scoring wire that allows for 360° efficient pressure-focused dilation [1] - It is the market's highest with four scoring wires, providing a larger scoring area and a rated burst pressure (RBP) of up to 20 atm, which offers a higher safety expansion margin [1] - The device excels in reducing the incidence of dissection and optimizing vascular preparation, particularly advantageous for complex lesions such as calcification [1] Group 2: Market Implications - The introduction of the Star Scar™ catheter provides a safer and more ideal option for coronary intervention treatments [1]

格隆汇12月11日丨蓝帆医疗(002382.SZ)公布，公司心脑血管事业部子公司山东吉威医疗制品有限公司 自主研发和生产的三类医疗器械产品"冠状动脉刻痕球囊扩张导管"（简称"星痕™"）通过国家药品监督 管理局（NMPA）的审查，正式获得中华人民共和国医疗器械注册证。星痕™冠状动脉刻痕球囊扩张导 管具有独特的螺旋环绕三角刻痕丝，可实现360°高效压力聚焦扩张；作为市场上最高 4 根刻痕丝的冠脉 刻痕球囊，具有更大的刻痕面积，额定爆破压力（RBP）高达 20atm，可以提供更高的安全扩张空间， 在降低夹层发生率、优化血管准备方面表现卓越，对于钙化等高阻力复杂病变，其优势尤为显著，为冠 状动脉介入治疗提供了更安全、更理想的选择。 ...

Core Viewpoint - The company, Bluestar Medical (002382.SZ), has successfully obtained a medical device registration certificate from the National Medical Products Administration (NMPA) for its self-developed and produced Class III medical device, the "Coronary Artery Scoring Balloon Dilatation Catheter" Group 1 - The product is developed and manufactured by the company's subsidiary, Shandong Jiwei Medical Products Co., Ltd. [1] - The approval signifies a significant milestone for the company's cardiovascular division [1]

Core Viewpoint - Blue Sail Medical (002382.SZ) announced that its subsidiary, Shandong Jiwei Medical Products Co., Ltd., has successfully developed and produced a Class III medical device, the "Coronary Angioplasty Balloon Catheter," which has received the medical device registration certificate from the National Medical Products Administration (NMPA) [1] Group 1 - The product is categorized as a Class III medical device, indicating its high risk and the need for stringent regulatory oversight [1] - The approval from NMPA marks a significant milestone for the company in expanding its product offerings in the cardiovascular sector [1] - This development may enhance the company's competitive position in the medical device market, particularly in cardiovascular treatments [1]

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-097 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 中国 NMPA 注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 关于子公司冠状动脉刻痕球囊扩张导管获得 近日，蓝帆医疗股份有限公司（以下简称"公司"）接到通知，公司心脑血管事业 部子公司山东吉威医疗制品有限公司自主研发和生产的三类医疗器械产品"冠状动脉 刻痕球囊扩张导管"（以下简称"星痕™"）通过国家药品监督管理局（NMPA）的审查， 正式获得中华人民共和国医疗器械注册证。现将相关情况公告如下： 一、获批产品基本信息 产品名称：冠状动脉刻痕球囊扩张导管 注册人名称：山东吉威医疗制品有限公司 注册证编号：国械注准20253032515 星痕™冠状动脉刻痕球囊扩张导管的成功获批，不仅为临床处理复杂冠状动脉病 1 变提供了又一精准高效的预扩张选择，也标志着蓝帆医疗心脑血管事业部在构建"PCI 优化全链路解决方案"的战略拼图更加完整，在 PCI 治疗中进一步成功实现从简单到 复杂病变整体解决方案的"一站式"供应，预期将对 ...

Group 1 - The core viewpoint of the article highlights the significant rise in global copper prices, driven by various factors including supply disruptions and increased demand from China and the U.S. [4][5][7] - As of December 3, 2023, LME copper prices reached a peak of $11,540 per ton, with further increases noted in early December [1][2]. - The global copper market is experiencing a supply-demand imbalance, with refined copper consumption projected at approximately 27.33 million tons in 2024, and China accounting for 58% of this demand [6]. Group 2 - The article discusses the impact of U.S. trade policies, including a proposed 50% tariff on imported copper semi-finished products starting August 1, 2025, which has led to a "rush" in global copper trade [7][12]. - The shift in copper supply chains is evident, with U.S. copper imports more than doubling in the first eight months of the year, reaching 1.19 million tons [8]. - The article notes that the rising copper prices are causing significant cost pressures on downstream manufacturing sectors, with copper constituting 20%-25% of the total cost of air conditioning units [14][15]. Group 3 - The article emphasizes the need for companies to adopt strategies such as risk hedging through futures markets and exploring alternative materials to mitigate rising copper costs [16][17]. - It also mentions that China is taking measures to address the copper supply issue, including increasing domestic copper recycling and securing mining rights in Mongolia and Laos [17]. - The long-term outlook suggests that even with high production levels, a global copper supply gap is expected to reach 20% by 2035, indicating ongoing challenges in the copper market [13].